80754-22-9Relevant academic research and scientific papers
Synthesis and Carbon-13 Nuclear Magnetic Resonance Assignments of Xenognosin
El-Feraly, Farouk S.,Hufford, Charles D.
, p. 1527 - 1530 (1982)
Xenognosin (1) is a modified flavonoid isolated from gum tragacanth, and it stands as the first natural host recognition substance for parasitic angiosperms.Xenognosin (1) was synthesized by converting umbelliferone (2) to the key aldehyde 6 which was tre
ARYLALKANOIC ACID DERIVATIVE
-
, (2008/06/13)
A compound represented by the formula (I): wherein Ar is an optionally substituted aromatic ring; Xa, Xc, Ya, Yc, Z1 and Z2 are each a bond, O, S, -CO-, -CS-, - CR3 (OR4) -, -NR5-, -SO-, -SO2-, -CONR6- or -NR6CO- (wherein R3, R4, R5 and R6 are as defined in the specification); Xb and Yb are each a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R1 is an optionally substituted hydrocarbon group; ring A is an optionally further substituted aromatic ring, provided that the ring should not be benzimidazole; n is an integer of 1 to 8; ring B is an optionally further substituted aromatic ring, provided that the ring should not be oxazole; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; and R2 is -OR8 or -NR9R10 (wherein R8, R9 and R10 are as defined in the specification) or a salt thereof, is useful as an agent for the prophylaxis or treatment of diabetes and the like.
THERAPEUTIC AGENT FOR DIABETES
-
Page/Page column 157, (2008/06/13)
The present invention provides an agent for the prophylaxis or treatment of diabetes, which is associated with a ferwer side effects such as body weight gain, adipocyte accumulation, cardiac hypertrophy and the like, and which contains a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.
ARYLALKANOIC ACID DERIVATIVE
-
Page/Page column 198, (2010/11/08)
A compound represented by the general formula (I): [wherein Ar represents an optionally substituted aromatic ring; Xa, Xc, Ya, Yc, Z1, and Z2 each represents a bond, O, S, -CO-, -CS-, -CR3(OR4)-, -NR5-, -SO-, -SO2-, -CONR6-, or -NR6CO- (R3, R4, R5, and R6 are as defined in the description); Xb and Yb each represents a bond or a C1-20 divalent hydrocarbon group; R1 represents an optionally substituted hydrocarbon group; ring A represents an aromatic ring (other than benzimidazole) which may be further substituted; n is an integer of 1-8; ring B represents an aromatic ring (other than oxazole) which may be further substituted; W represents a C1-20 divalent saturated hydrocarbon group; and R2 represents -OR8 or -NR9R10 (R8, R9, and R10 are as defined in the description)] or a salt of the compound. It is useful as a preventive/therapeutic agent for diabetes, etc.
ALKANOIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF
-
Page/Page column 56, (2008/06/13)
An alkanoic acid derivative useful as a prophylactic or therapeutic agent of diabetes mellitus, hyperlipidemia, impaired glucose tolerance and the like can be provided by a compound represented by the formula wherein R1 is an optionally substituted 5-membered aromatic heterocyclic group; X is a bond and the like; Q is a divalent hydrocarbon group having 1 to 20 carbon atoms; Y is a bond and the like; ring A is an aromatic ring optionally further having 1 to 3 substituents; Z is -(CH2)n-Z1- (n is an integer of 1 to 8 and Z1 is an oxygen atom and the like) and the like; ring B is a pyridine ring optionally further having 1 to 3 substituents, and the like; U is a bond and the like; W is a divalent hydrocarbon group having 1 to 20 carbon atoms; and R3 is -OH and the like, provided that, when ring B is a benzene ring optionally further having 1 to 3 substituents, U should be a bond, or a salt thereof.
